1.. Introduction {#s1}
================

Cell-adhesion events mediated by VE-cadherins, catenins, and extracellular matrix (ECM) proteins play decisive roles in the development of vascular endothelial cells (ECs) and the maintenance of the vascular system.^[@CVW090C1]--[@CVW090C6]^ In this regard, the pivotal roles played by β-catenin and VE-cadherin in the formation of adherens junctions (AJs) during the development and maintenance of blood vessels have been investigated.^[@CVW090C1]--[@CVW090C6]^ For example, the deletion of *VE-cadherin* (*Cdh5*) was found to inhibit vascular remodelling and induce degradation of vascular integrity, resulting in early embryonic lethality.^[@CVW090C3],[@CVW090C4]^ The conditional deletion of the *β-catenin* gene in ECs induces a defective vascular pattern and reduces vascular integrity.^[@CVW090C5]^ Cell adhesion mediated by binding of integrins to ECM proteins such as fibronectin and laminins also plays an equally important role in several aspects of vascular development and differentiation.^[@CVW090C1],[@CVW090C2]^ A key role for β-catenin beyond binding to VE-cadherin has been established in the transduction of Wnt signals.^[@CVW090C7]--[@CVW090C10]^ Canonical Wnt signalling propagates translocation of stabilized β-catenin to the nucleus, where it coactivates the transcription factor T-cell factor/lymphocyte enhancer binding factor (TCF-1/LEF-1).^[@CVW090C9],[@CVW090C10]^ In addition, β-catenin also plays a key role in EC and heart valve development and activates transcription factors such as Er71/Etv2, which plays a key role in the generation of Fetal liver kinase (Flk)1^+^ ECs.^[@CVW090C11],[@CVW090C12]^ However, the molecular mechanisms underlying these processes are not clearly understood.

Lipid phosphate phosphatases (LPPs), most recently changed the nomenclature to phospholipid phosphatases (PLPPs), are encoded by phosphatidic acid phosphatases (*PPAP2b*), represent a family of ecto-enzymes that are known to cleave the phosphate group from sphingosine-1-phosphate (S1P) and its structural homologues.^[@CVW090C13]--[@CVW090C15]^ The three major isoforms LPP1, LPP2, and LPP3 are distributed unevenly in the endoplasmic reticulum, cytosol, plasma membrane, and caveolae.^[@CVW090C13]--[@CVW090C17]^ A more recent study reported the localization of LPP3 to cell--cell contact sites.^[@CVW090C18]^ Previous studies have documented the ability of LPPs to down-regulate cell signalling.^[@CVW090C13]--[@CVW090C17]^ We previously detected LPP3 in a bioassay for angiogenesis and reported the ability of LPP3 to regulate cell-adhesion events.^[@CVW090C19],[@CVW090C20]^ We also showed that anti-LPP3 antibody blocked basic fibroblast growth factor (bFGF)- and vascular endothelial growth factor (VEGF)-mediated angiogenic activities of ECs.^[@CVW090C21]^ In addition, we reported the ability of LPP3 to regulate tumour growth *in vivo.*^[@CVW090C21]--[@CVW090C23]^

Conventional deletion of the *Lpp3* gene results in severe embryonic developmental abnormalities such as defective formation of the chorioallantois, placenta, and yolk sac vasculature, suggesting a critical function of Lpp3 in early mouse development.^[@CVW090C24]^ Thus, complete analysis of the *in vivo* function of Lpp3 is hampered by early embryonic lethality.^[@CVW090C24]^ The results obtained on *Mx1^Cre^*- or *Cdh5^CreERT2^*-mediated deletion of *Lpp3* indicated its ability to control the Lpp3--S1P steady state in relation to thymic T-cell egression.^[@CVW090C25]^ Lpp3 deletion altered smooth muscle cell phenotypes^[@CVW090C26]^ and vascular inflammation.^[@CVW090C27]^ These studies described the ability of Lpp3 to act as an enzyme; however, they did not address the behaviour of ECs in relation to cardiovascular development. Therefore, we generated *Lpp3^fl/fl^* mice and crossed them with the *Tie2^Cre^* transgenic line; we used these mice to investigate the crucial role played by *Lpp3* in EC barrier integrity and cardiovascular development.

2.. Methods {#s2}
===========

2.1. Materials and methods {#s2a}
--------------------------

### 2.1.1. Antibodies and reagents {#s2a1}

Production, characterization, and use of rabbit anti-LPP3 antibody have been previously described,^[@CVW090C19]--[@CVW090C22]^ and anti-LPP3 antibodies were used at 1.5 µg/mL concentration. Mouse anti-VCIP/LPP3 (39-1000) monoclonal antibody (mAb) was purchased from Invitrogen (Carlsbad, CA, USA), used at 2.0 µg/mL concentration. Rabbit-anti-LPP2 polyclonal antibody (pAb) was obtained from Exalpha Biologicals, Inc. (Shirley, MA, USA), prepared and used at 2.0 µg/mL. Rabbit anti-Cyclin-D1 (2978) and rabbit anti-cleaved caspase-3 (9664) were bought from Cell Signaling Technology, Inc. (Denvers, MA, USA), and these antibodies prepared and used at 1.25 µg/mL. Mouse anti-β-catenin (SC-7963), anti-VE cadherin (SC-9989 and SC-64586), mouse anti-p120 catenin (SC-23872), anti-DLL4 (SC-28915), mouse anti-p53 (SC-6243), and mouse anti-p21 (SC-397) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and these antibodies were used at 1.5 µg/mL concentrations. Rabbit anti-LPP1 (AV42146), rabbit-anti-β-catenin (C7738 and C2206), and anti-Fibronectin were purchased from Sigma (St. Louis, MO, USA), and these antibodies were prepared and used at 1.75 µg/mL concentration. Rat anti-Flk1 (Avas12a1) mAb was purchased from Novus Biologicals (Littleton, CO, USA), used at a concentration of 2.0 µg/mL. Rabbit anti-vWF (AB7356), anti-Cre (69050-3), and thrombin (605206) were purchased from EMD-Millipore (Billerica, MA, USA), and anti-vWF and anti-Cre antibodies were prepared and used at 1.25 µg/mL concentrations. Secondary antibodies were purchased from Promega Corp. (Madison, WI, USA) or from KPL Inc. (Gaithersburg, MD, USA). Growth factor-reduced Matrigel and rat anti-PECAM-1 (CD31) antibody (550274) were bought from BD Bioscience (Franklin Lakes, NJ, USA). Vaso-TACS *in situ* apoptosis detection kit (4826-30-K) was purchased from Trevigen (Gaithersburg, MD, USA). Substrates and alkaline phosphatase for histological experiments were purchased from Vector Labs (Burlingame, CA, USA). Human umbilical vein endothelial cells and human lung microvascular endothelial cells (LMVECs) were purchased from Lonza (Allendale, NJ, USA) and EndoGRO-Media from Millipore Inc. (Billerica, MA, USA). All shRNA retroviral constructs were purchased from Origene (Rockville, MD, USA). 5-Bromo-2-deoxyuridine (BrdU) labelling and detection kit III (1144461100) was purchased from Roche (Nutley, NJ, USA).

2.2. Animal studies and generation of *Lpp3^Δfl/Δfl^* (aka *Lpp3^ECKO^* or *MT*) mice {#s2b}
-------------------------------------------------------------------------------------

Methodologies for animal care including breeding, genotyping, and collection of embryos were approved by the University of Illinois at Chicago Animal Care Committee. The animal experiments were performed conform the NIH guidelines (guide for the care and use of laboratory animals) or the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes. To investigate the role of Lpp3 in the development of the vasculature, we employed the *Cre/loxP* system and *Tie2^Cre^* transgenic animals.^[@CVW090C28]^ *Tie2* is an EC-specific receptor and the promoter has mostly EC-specific expression, however, also expressed by monocytes and macrophages. Male *B6.Cg-Tg(Tek-cre)12Flv/J* and male *B6.129S4-Gt(ROSA)26Sortm1(FLP1)Dym/JRainJ*^[@CVW090C29]^ mice were purchased from Jackson Labs (Bar Harbor, MN, USA), backcrossed with C57BL mice for six generations. Using mouse *Lpp3* exon-3 probe, we screened and obtained five bacterial artificial chromosomes (BAC) (RPC122-278N3, -258K13, -268N13, -268H13, -258G15; Children\'s Hospital Oakland Research Institute, Oakland, CA, USA). Exons 3 and 4 encode a lipid phosphatase domain and the integrin binding (RGE) sequence. Polymerase chain reaction (PCR) using BAC as template was used to generate a 3.9 kb 5′ arm of homology, a 1.2 kb 'floxed' sequence containing exons 3 and 4, and a 3.0 kb 3′ arm of homology (*Figure [1](#CVW090F1){ref-type="fig"}A*). These fragments were used in the construction of a gene-targeting vector. The *Lpp3* gene targeting strategy entailed incorporation of the recognition sequences for two site-specific recombinases, *Cre* and *Flp*, into the *Lpp3* gene using homologous recombination. This vector incorporates 1.8 kb fragment containing a PGK-*Neomycin* resistance cassette that is flanked by *Flippase* recognition target sites (FRT) into the intron between exons 4 and 5. Exons 3 and 4 of *Lpp3* are placed between tandem *loxP* sites, such that these coding segments can be deleted *in vivo* in a *Cre*-recombinase dependent manner (*Figure [1](#CVW090F1){ref-type="fig"}A*). The 5′ and 3′arms of homology are needed to allow for homologous recombination. Correctness of targeting construct was determined by DNA sequencing and restriction digests. ES cell clones were identified by PCR using *Neomycin* (*Neo*) cassette-specific primer, For-5′-*CTTCCTCGTGCTTTACGGTATC*-3′and Rev-5′-*GTAGCTAGCACAATGACAAG*-3′ (from 3′arm). Targeted ES cell clones were also confirmed by Southern blot analysis with 5′ and 3′probes (*Figure [1](#CVW090F1){ref-type="fig"}A*), and the targeting frequency was 8 out of 384 clones (2.0%). Aggregation, breeding of chimeras, and the germline *Lpp3^loxP−Neo/+^* were generated by inGenious Targeting Laboratories (Stony Brook, NY, USA). Male *Lpp3^loxP−Neo/+^* mice were crossed with *Rosa.Flp1*-recombinase (female) transgenic mice, which removed the neomycin cassette (*FRT*-*Neo*-*FRT*), leaving two *loxP* sites flanking exons 3 and 4, resulting in *fl-Lpp3^ΔNeo/WT^* mice. To avoid possible confusing effects of other genetic variables in our phenotypic analyses, these mice were backcrossed for 12 generations in an isogenic strain to generate *fl-Lpp3^ΔNeo/WT^* in C57BL background. Next, *fl-Lpp3^ΔNeo^*^/*WT*^ mice were crossed with their siblings of same genotype to produce *fl-Lpp3^ΔNeo^/fl-Lpp3^ΔNeo^* (hereafter called *Lpp3^fl/fl^*; 25%) of C57BL background. Finally, *Lpp3^fl/fl^* (female) were crossed with *B6.tg.Tie2^Cre^* (male) transgenic line^[@CVW090C28]^ in C57BL background to generate *Lpp3*^Δ*fl*/Δ*fl*^ (25%), henceforth called *Lpp3*^ECKO^ or mutant (*MT*) embryos. All newborn mice and embryos were genotyped by PCR analyses of genomic DNAs for the presence of both wild-type (*WT*) and *MT* alleles. *B6.Tie2^Cre^* littermates were used as *WT* control. For genotyping *fl-Lpp3^Neo^/fl-Lpp3^Neo^* and *Lpp3^fl/fl^* siblings, *Lpp3*-For-5′-*GTACTGGATCGATAGCACACACTC*-3′ and *Lpp3*-Rev-5′-*AGATACAAATAGATCTTCAAGGAC*-3′primers were used. For genotyping the *tg.Tie2^Cre^* transgene, *Cre*-For-5′-*GATATCTCACGTACTGACGG*-3′ and *Cre*-Rev-5′-*TGACCAGAGTCATCCTTAGC*-3′ primers, which amplify a 300 bp PCR product, were used.

2.3. Isolation of mouse ECs, BrdU incorporation assay, and microscopy {#s2c}
---------------------------------------------------------------------

Fluorescence-activated cell sorting (FACS) and isolation of ECs from mouse embryonic stem cells and induced pluripotent stem cells have been previously described by us.^[@CVW090C30]--[@CVW090C32]^ Briefly, for isolation of mouse ECs, we used anti-mouse-Flk1 (CD309) and anti-mouse-CD31 microbeads (Miltenyi Biotec GmbH, San Diego, CA, USA). Mouse embryos at developmental stage at E11.5 were collected, washed three times with cold 1× PBS, pH 7.4; heart, lungs, brains, and livers were enzymatically dissociated in DMEM containing collagenase/dispase/0.1% trypsin/1.0 mM EDTA, for 30 min at 37°C in a CO~2~ incubator. Cells were centrifuged for 5 min at 400 *g* at 4°C. Cell pellets were re-suspended in DMEM + DNase I (10 units/mL), passed through Falcon cell strainer with a pore size of 70 µm, and collected using 50 mL Falcon centrifuge tube. Thereafter, cells were re-suspended in DMEM and sorted with anti-Flk1-magnetic beads (Miltenyl Biotec). Flk1^+^ cells were cultured in serum-free EndoGro medium supplemented with bFGF (10 ng/mL), VEGF (50 ng/mL), and Wnt3a (50 ng/mL) for 18 h. Next day, these cells were detached with 0.1% trypsin/EDTA and sorted again with anti-CD31-magnetic beads. Flk1^+^/CD31^+^ (double-positive) cells were plated at a density of 2 × 10^4^ cells onto 0.2% gelatine coated 6-well dish in serum-free EndoGro medium supplemented with bFGF, VEGF, and Wnt3a. We also generated Lpp3-deficient ECs from *Lpp3^fl/fl^* embryos; accordingly, *Lpp3^fl/fl^* ECs were infected for 18 h with recombinant adenovirus particle encoding the *Cre/RFP*, in which the RFP signal was used to assess infection efficiency. These cells were immediately used for flow cytometry, biochemical experiments, and gene expression analyses as previously described.^[@CVW090C30]--[@CVW090C32]^

For biochemical experiments, ECs isolated from Flk1^+^/CD31^+^ (double-positive) cells were grown for 6 days in EndoGro media supplemented with 5% FBS; bFGF (10 ng/mL), VEGF (50 ng/mL), and Wnt3a (50 ng/mL); and insulin, transferrin, and selenium (1× ITS, Gibco-BRL). For proliferation assays, ECs were seeded on cover slips pre-coated with 0.2% gelatine and incubated in media containing BrdU (10 µM) for overnight at 37°C in a CO~2~ incubator, thereafter stained with anti-BrdU labelling kit (Roche). *Figure [7](#CVW090F7){ref-type="fig"}A* represents the timeline of BrdU experiment. For quantification, at least 10 microscopic fields were selected randomly, counted and photographed on each coverslip using Zeiss microscope and Canon power shot A640 camera supported by Canon Zoom-in software. Experiments were repeated at least three to five times, with at least three technical replicates.

2.4. Whole mount immunohistochemistry {#s2d}
-------------------------------------

After timed mating, gravid mice were euthanized by cervical dislocation.^[@CVW090C33],[@CVW090C34]^ Embryos harvested by caesarean section from E11.5, E12.5, and E13.5 were fixed in freshly prepared 2% *p*-formaldehyde in PBS for 4 h at 4°C.^[@CVW090C32],[@CVW090C33]^ Whole mount immunohistochemistry protocol has been described by Courtney Griffin lab.^[@CVW090C35]^ Fixed embryos were treated with PBS containing 0.15% H~2~O~2~, 0.1% NaN~3~ for 1 h at 4°C, thereafter incubated in blocking solution (PBS-MBT, 2% carnation dry milk, 0.2% BSA, 0.6% goat serum, and 0.1% Triton X-100 in PBS, pH 7.4) at 4°C for 1 h. Next, the samples were incubated in biotinylated rat anti-mouse CD31 antibody (1:50 in PBS-MBT) for 48 h, followed by wash in PBS-MT (PBS, pH 7.4 containing 2% carnation dry milk and 0.1% Triton X-100) for five times, 1 h each at room temperature. Next, the samples were incubated in 1:200 diluted peroxidase-labelled goat anti-rat IgG (KPL) at 4°C for overnight. Next day, samples were washed for five times in PBS-MT for 1 h each at room temperature. Peroxidase-stained embryos were visualized by using a DAB kit (Vector Labs). Stained embryos were immersed in 50% glycerol, and vascular developments of the embryos photographed using Zeiss stereo microscope at room temperature.

2.5. TUNEL apoptosis assay {#s2e}
--------------------------

Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labelling (TUNEL) assays were performed on paraffin-embedded sections prepared from E13.5 using EC-specific VasoTACS *in situ* apoptosis detection kit (Trevigen).^[@CVW090C36],[@CVW090C37]^ For imaging and quantification, 20 microscopic fields were selected randomly, photographed with Zeiss Apotome microscope acquired using AxioVision software at room temperature. TUNEL-positive ECs were quantified in both MT and their WT littermates. Experiments were repeated at least three times.

2.6. Immunohistochemistry and microscopy {#s2f}
----------------------------------------

Staining and microscopy methods have been previously described.^[@CVW090C19],[@CVW090C22],[@CVW090C30]^ In brief, paraffin-embedded sections prepared from E13.5 were rehydrated in graded ethanol then treated with 3% hydrogen peroxide (H~2~O~2~) for 20 min, next the samples were blocked with 5% normal goat serum diluted in 1× PBS, pH 7.4, for 1 h. Sections were incubated in primary antibodies for 1 h (1:200 dilution, ∼2.0 µg/mL). After PBS wash, slides were incubated with appropriate secondary antibodies (dilution 1:300) for 1 h at room temperature. Stained sections were examined, images photographed with a Zeiss Apotome fluoroscope, and scored for staining intensity as previously described.^[@CVW090C19],[@CVW090C22],[@CVW090C30]^

2.7. Transmission electron microscopy {#s2g}
-------------------------------------

E13.5, both *WT* (*B6.tg.Tie2^Cre^* siblings) and *MT*, were fixed in 0.1 M cacodylate buffer, pH 7.4. All transmission electron microscopy (TEM) processing were carried out by the University of Illinois at Chicago Research Resources Center Electron Microscopy Service core facility. Images were recorded using JEM-1220 TEM and Erlangshen ESW1000W 785 digital camera supported by Gatan digital micrograph version 1.7.1 software.

2.8. Cell culture, shRNA transfection, and western blot analysis {#s2h}
----------------------------------------------------------------

For immunostaining, ECs were plated on coverslips and stained as previously described.^[@CVW090C19]--[@CVW090C22]^ Lentivirus shRNA-mediated knockdown was performed as previously described,^[@CVW090C29]--[@CVW090C31]^ and efficiency evaluated by western blot (WB) analysis. For WB, cells were solubilized in cell lysis buffer containing 20 mM Tris (pH 7.5), 1.0% Triton X-100, 0.2% NP-40, 1 mM EDTA, and 150 mM NaCl, in presence of freshly added protease inhibitors cocktail as previously described.^[@CVW090C19],[@CVW090C22]^ For quantification, signal band intensity was measured using ImageJ (NIH software). All WB images shown are representative, and the images within comparison groups are obtained from the same nitrocellulose membrane exposed to X-ray films exactly for same time.

2.9. Transendothelial electrical resistance assays {#s2i}
--------------------------------------------------

To assess EC monolayer barrier integrity, real-time transendothelial electrical resistance (TER) changes in EC monolayer was recorded using the ECIS system (Applied Biophysics, Troy, NY, USA) as previously described.^[@CVW090C38],[@CVW090C39]^ ECs isolated from *WT* and *MT* mice and LMVECs were plated on gold electrode (Applied Biophysics) slides for 72 h to make a uniform monolayer. ECs were then treated with *control* shRNA or *Lpp3*-shRNA. After 6 h, Lpp3-depleted cells were re-transfected with *β-catenin* cDNA or *p120-catenin* cDNA. Plates were then positioned in lock-in amplifier with a constant current of 1.0 µA supplied by a 1 V, 4000 Hz alternating current signal between the small electrode and the larger counter electrode. The voltage between the small and the large electrodes was monitored in all of the different wells and recorded with ECIS-Applied Biophysics software. After 25 min of recording the baseline, the EC monolayers were treated with 50 nM of thrombin, thereafter thrombin-induced changes in resistance was monitored for about next 2 h. Efficiency of shRNA-mediated knockdown and cDNA transfection in HMVEC-L cells was assessed by WB (*Figure [6](#CVW090F6){ref-type="fig"}C*).

2.10. Endothelial branching point structure assay {#s2j}
-------------------------------------------------

Twenty-four-well dishes were coated with 100 µL Matrigel at 37°C for 45 min. Embryonic ECs isolated from E13.5 (as described above) were re-suspended in 200 µL of EndoGro media, thereafter plated onto the Matrigel. After attachment of ECs to the matrix, media containing bFGF (10 ng/mL), VEGF (50 ng/mL), and Wnt3a (50 ng/mL) were added. Thereafter, dishes were returned to 37°C humidified CO~2~ incubator. After 48 h, branching point structures were evaluated, 10 random microscopic fields at ×20 magnifications were counted, and representative images were photographed with a Zeiss microscope and Canon power shot A640 camera as previously described.^[@CVW090C22],[@CVW090C30]^

2.11. Quantitative real-time polymerase chain reaction assay {#s2k}
------------------------------------------------------------

Total RNAs were isolated from ECs with the use of TRIzol reagent (Invitrogen); quantification and assays were performed as previously described.^[@CVW090C30],[@CVW090C31]^ Primer pairs for mouse *Lpp3*, *Lpp2*, *Cyclin-D1*, *Fibronectin*, *VE-cadherin*, *Flk1*, *Klf2*, *Klf4*, and *Hprt* were purchased from IDT DNA (Skokie, IL, USA). *Hprt* was used as an internal control to correct for the concentration of cDNA in different samples. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using Power SYBR Green RNA-to-CT™ 1-step kit (Applied Biosystems) using gene-specific primer pairs (*Table [1](#CVW090TB1){ref-type="table"}*). Table 1Oligonucleotides used for amplifying mouse transcripts through qRT-PCRGene nameSequenceGenbank accession number1*Lpp3*For: 5′-TCT GAC TAC AAG CAT CAT CCT AGC-3′\
Rev: 5′-GCT CGT CTT AGT CTT GAA GAG GTC-3′NM_080555.22*Lpp2*For: 5′-CCT GCC TCA CGC TAT ATG TGC-3′\
Rev: 5′-CAC CAA GAA GAA CTG AAC AGT GG-3′AF123611.13*Flk1*For: 5′-GAA GAG CTG AAA ACT CTG GAA GAC-3′\
Rev: 5′-ACA GAC TCC CTG CTT TTA CTG G-3′NM_010612.24*VE-cadherin*For: 5′-CTG GTG GCC ATC TTC CTC T-3′\
Rev: 5′-GCA GGA TGA TCA GCA AGG TA-3BC054790.15*Fibronectin*For: 5′-CCA CAC CTA CAA CCA GTA TAC ACA-3′\
Rev: 5′-AGC ACT CAA TGG GGC AAT TTA C-3′BC138421.16*Cyclin-D1*For: 5′-CTC TTG CAT GGA AGT GTC TCC TAC-3′\
Rev: 5′-AGG TAG GCT GAC ATG AGG AAA TC-3′BC044841.17*Klf2*For: 5′-AAC TGC GGC AAG ACC TAC AC-3′\
Rev: 5′-TCC TTC CCA GTT GCA ATG AT-3′NM_008452.28*Klf4*For: 5′-ACC CAC ACT TGT GAC TAT GCA G-3′\
Rev: 5′-AGT CAC AGT GGT AAG GTT TCT CG-3′NM_010637.39*Hprt*For: 5′-GTG AAA AGG ACC TCT CGA AGT GTT-3′\
Rev: 5′-ATA GTC AAG GGC ATA TCC AAC AAC-3′J00423.1

2.12. Statistics {#s2l}
----------------

Values are means ± SEM. Statistical significances were calculated by standard *t*-test or one-way analysis of variance with Bonferroni *post hoc* test for more than two conditions, and values of *P* \< 0.05 were considered statistically significant.

3.. Results {#s3}
===========

3.1. *Tie2^cre^*-mediated *Lpp3* deletion causes embryonic lethality in two waves and severe defects in vascular development {#s3a}
----------------------------------------------------------------------------------------------------------------------------

The *Lpp3* genomic locus, restriction sites, targeting vector schematic, and diagnostic Southern blots of targeted ES cell clones are shown in *Figure [1](#CVW090F1){ref-type="fig"}A*. Representative PCR genotyping results for *WT*, *Lpp3^loxP−Neo/WT^*, and *Lpp3^loxP−Neo/loxP−Neo^* mouse tail DNAs are shown in *Figure [1](#CVW090F1){ref-type="fig"}B*, and a simplified breeding scheme is shown in *Figure [1](#CVW090F1){ref-type="fig"}C*. To investigate the role of Lpp3 in *Tie2^Cre^-*expressing cellular compartments, female *Lpp3^fl/fl^* mice were crossed with male B6.*tg.Tie2^Cre^* transgenic mice. *Tie2^Cre^*-mediated elimination of exons 3 and 4 generated *Lpp3*-null MT embryos, which are expected to be mostly EC specific; however, Lpp3 was also expressed in non-vascular tissues. Through this breeding scheme (*Figure [1](#CVW090F1){ref-type="fig"}C*), we observed early on that pregnant mothers produced only 3 or 4 pups per litter, and the genotype confirmed these pups were either *Tie2^Cre^* or *Lpp3^fl/^^wt^*. Therefore, timed matings were carried out and embryos were harvested from the pregnant mothers; subsequently, these embryos were subjected to microscopic phenotypic analyses. The microscopic examination provided indication that some of the embryos were blue and some were small ([Supplementary material online, *Figure S1A--D*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvw090/-/DC1)), and these abnormal embryos died between E8.5 and E10.5 and we considered this as the first wave of lethality. Microscopic analysis of haematoxylin and eosin (H&E)-stained paraffin sections prepared from dead embryos indicated the presence of ECs and red blood cells but poorly developed cardiovascular structures. The analyses of E11.5 to E13.5 indicated that *Lpp3*^ECKO^ (also indicated as *MT*) embryos likely died *in utero* due to the defects in vascular structures and haemorrhage (*Figure [1](#CVW090F1){ref-type="fig"}D* and [Supplementary material online, *Figure S1E--I*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvw090/-/DC1)), and we attributed this event to the second wave of lethality. To confirm the loss of Lpp3 in ECs, we isolated ECs from these embryos; these ECs showed the absence of the *Lpp3* transcript or loss of the Lpp3 protein. Thus, *MT* embryos died in two waves. Genotyping of ECs isolated from these embryos confirmed that heterozygote embryos appeared normal, while homozygote (*Lpp3*^ECKO^) embryos did not survive beyond E13.5, as dead embryos were frequently found *in utero*, indicating late embryonic lethality. Heterozygous mice (*fl-Lpp3^ΔNeo^*^/WT^) appeared to be phenotypically normal, and their viability was similar to that of *WT* littermates. To perform phenotypic analyses, *WT-* and *MT*-embryos were collected at specific developmental stages (*Table [2](#CVW090TB2){ref-type="table"}*) and subjected to microscopic analyses. Normal vascular patterning was also seen in normal head and tails at E12.5 ([Supplementary material online, *Figure S2A--C*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvw090/-/DC1)). However, in *MT* embryos, severe haemorrhage was visible in the head region (*Figure [1](#CVW090F1){ref-type="fig"}D*, bottom right panels; [Supplementary material online, *Figure S2D*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvw090/-/DC1)). In addition, we observed defective sprouting of blood vessels in the tails of the *MT*-embryos but not in *WT*-tails ([Supplementary material online, *Figure S2E* and *F*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvw090/-/DC1)). These results indicated that *Tie2^Cre^*-mediated *Lpp3* deletion produces embryonic lethality in two waves. Table 2After timed matings, embryos were collected, and their viability and genotypes determinedDays oldWTHT (hetero)MTTotal1E9.53498261582E10.5153118^a^643E11.5305612^a^984E12.512268^a^465E13.58156^a^29[^1] Figure 1Severe localized haemorrhages and lethality in *Lpp3^ECKO^* embryos. (*A*) Top left: strategy for deletion of *Lpp3* alleles and targeting vector. The *Tie2*^Cre^-mediated excision of the floxed allele is expected to generate a null *Lpp3* allele in ECs. Top right panels: Southern blot analyses of DNAs from ES cells to determine homologous recombination. DNAs digested with *Bam*HI enzyme and hybridized with indicated probes. In addition to ∼10.8 kb wild-type (*WT*) fragments, we show ∼12.6 kb novel fragments hybridized with both 5′ and 3′ genomic repeat-free probes. (*B*) Representative images of EtBr-stained PCR-genotyping of indicated alleles. (*C*) Simplified breeding scheme used for producing *Lpp3^ECKO^* (*MT*) embryos. (*D*) Top panels: representative images of *WT* (*tg.Tie2^Cre^*) embryos collected on indicated days showing normal growth and vascular development; right panel: head region of the same *WT* embryo. Bottom panels: representative images of indicated *Lpp3*^ECKO^ embryo showing severe haemorrhage (white arrows). WT, wild-type; MT, mutant; Molecular weight is shown in kilobase pairs (kb). The targeting vector diagrams are not shown to exact scale. Magnifications are as shown. Images are representative of three independent experiments in which 9 (WT) and 12 (MT) separate embryos for each time points were evaluated (*n* = 9--12); for more details, please see statistics in the Methods section.

3.2. Embryonic lethality in *Lpp3^ECKO^* is accompanied by defects in developing blood vessels {#s3b}
----------------------------------------------------------------------------------------------

To determine the role of Lpp3 in ECs, microscopic and histological analyses were performed. Anatomical and histological examinations of *WT* (*tg.Tie2^Cre^*) and *MT* (*Lpp3^ECKO^*) embryos revealed no gross abnormalities prior to E11.5. Detailed microscopic analysis of H&E-stained sections of E13.5 *MT*-embryos revealed severe haemorrhage in the brain cavity. These haemorrhages were most likely one of the main causes of embryonic death. Although it was difficult to precisely determine the primary sites of haemorrhage based on the microscopic examination, the haemorrhages appeared to extend mainly to the frontal regions of the brain cavity. To determine whether vascular leakage was due to an altered EC phenotype, we performed whole-mount staining with a monoclonal anti-CD31 antibody to visualize the vascular system (*Figure [2](#CVW090F2){ref-type="fig"}A--H*). Anti-CD31 staining of *MT* embryos revealed developing neovessels with patches showing haemorrhagic events inside the head region (*Figure [2](#CVW090F2){ref-type="fig"}B--D*). We also observed several blunt-ended vessels; however, there was no such defect in the *WT* embryos (*Figure [2](#CVW090F2){ref-type="fig"}A--D*). Staining with anti-CD31 showed normal vascular development in the *WT-*eye (*Figure [2](#CVW090F2){ref-type="fig"}E)*, whereas the formation of the vascular network in the *MT*-eye (*Figure [2](#CVW090F2){ref-type="fig"}F*) was not as extensive as that in the *WT-*eye. The gross vascular network in the *MT*-eye seemed to be incomplete and often failed to form stable vascular network connections (*Figure [2](#CVW090F2){ref-type="fig"}F*). Retinal neovessel formation occurs immediately after birth, and prior to that, the hyaloid vasculature supplies the inner eye and lens; immediately after birth, these hyaloid vessels start to regress as the neovessels form. The neovessels in the *MT*-hyaloid were reduced. Anti-CD31 staining of the *MT* embryos showed haemorrhages in the early vascular plexuses (*Figure [2](#CVW090F2){ref-type="fig"}D*). We also found impaired vascular remodelling in the yolk sac in *Lpp3*-deficient embryos (*Figure [2](#CVW090F2){ref-type="fig"}G* and *H*). Trabeculation and the growth of compact wall of the myocardium are morphogenetic events that are known to be critical for the development and function of the ventricular walls. In addition, the interactions between ECs in the developing heart and adjacent cardiomyocytes provide intimate signalling cross-talk to control cardiac development, contractile activities, and rhythmicity. Since EC--cardiomyocyte interactions play a key role in cardiac growth, we stained *WT*- and *MT*-heart sections with H&E. Examination of the *WT*-heart showed the presence of apparently normal epicardium, myocardium, and endocardium, with an expected level of trabeculation and the growth of compact wall, and the presence of epicardium (*Figure [3](#CVW090F3){ref-type="fig"}A, B*, and *G*); in contrast, the *MT*-heart showed significantly decreased trabeculation, insufficient growth of the compact wall, and hypocellular myocardial wall defect accompanied by thin epicardium (*Figure [3](#CVW090F3){ref-type="fig"}C, D*, and *H*). Additional images (*Figure [3](#CVW090F3){ref-type="fig"}E* and *F*) represent *MT*-embryo showing decreased trabeculation and insufficient growth of compact wall. Together, these results indicate that the *Tie2^Cre^-*mediated deletion of *Lpp3* affects embryonic cardiovascular development. Figure 2CD31 staining reveals leaky vasculature in developing *Lpp3^ECKO^* (*MT*) embryos. (*A*) *WT* mice embryo reveals normal developing neovessels; (*B*) magnified image of the head region of *WT* embryo; (*C*) magnified images of eye hyaloid vasculature in *WT* embryo; (*D*) normal vascular patterning of the yolk sac of *WT* embryo with normal branching point networks. (*E*) *MT* embryo reveals abnormal neovessels with haemorrhage (black arrows); (*F*) *MT* embryos with vascular leakage (arrows). *MT* embryos show defects in developing vasculature (white arrows). (*H*) MT yolk sac shows lack of vascular network formation. (*I* and *J*) Magnified images of vascular structures. Experiments were carried out at least two times. Magnifications are as shown. Images are representative of three independent experiments in which 6 (WT) and 9 (MT) separate embryos were stained with anti-CD31 (*n* = 6--9). Figure 3Insufficient trabeculation and decreased growth of the compact wall in *Lpp3^ECKO^* heart. H&E staining of sagittal sections heart prepared from E11.5-day-old embryos showed insufficient development of heart associated with decreased trabeculation and reduced growth of the compact wall in *MT*-embryos. (*A* and *B*) Normal heart development associated with normal growth of the atrium (AT) and the ventricle (VN) that are separated by the endocardial cushion (EC), and presence of trabeculation and normal growth of the compact wall in *WT-*embryo heart. The outer myocardial (MY) muscle and inner endocardial (EN) endothelium are discernible, and epicardium (EPI) is well developed. Decorative myocardial trabeculae (TR) are lined by a layer of endocardial ECs. (*C* and *D*) *MT*-embryo section through the heart shows reduced trabeculation and decreased growth of the compact wall resulting in insufficient cardiac development. *(E* and *F*) Another example of defective cardiac development associated with decreased trabeculation and decreased growth of the compact wall in *MT*-embryo. (*G*) Quantification of trabeculation layer (µm). (*H*) Quantification of thickness of compact wall (µm). For quantifications, 9--12 embryos were used for WT- (*n* = 9) and MT-heart (*n* = 12) sections. From each embryo, at least three H&E stained slides were prepared and examined through ×10 objectives. Each data point in the bar graph (*Figure [3](#CVW090F3){ref-type="fig"}G* and *H*) represents average of three slides obtained from same embryo (for additional details, please see statistics in the Methods section). \**P* \< 0.05 vs. control.

3.3. *Lpp3*-deficient ECs show increased susceptibility to apoptosis {#s3c}
--------------------------------------------------------------------

To determine if the vascular defects observed in *MT (Lpp3^ECKO^*) embryos were due to EC apoptosis, paraffin-embedded sections of E13.5 *WT* (*tg.Tie2^Cre^* embryo) and *MT* embryos were subjected to immunochemical staining (*Figure [4](#CVW090F4){ref-type="fig"}A--H*). *WT*-embryos showed normal (basal) apoptosis (*Figure [4](#CVW090F4){ref-type="fig"}A, C, E*, and *I*), whereas *MT* embryos exhibited a 40 ± 4.5% increase in TUNEL^+^ ECs (*Figure [4](#CVW090F4){ref-type="fig"}B, D, F*, and *I*) in the head region, where vascular leakage and haemorrhagic events were detected. At higher magnification, the WT-sections showed very few TUNEL^+^ ECs, whereas in MT-sections, TUNEL^−^ positive cells were mostly ECs (*Figure [4](#CVW090F4){ref-type="fig"}H)*. Although VasoTac primarily detects apoptotic ECs, it may also stain smooth muscle cells; nevertheless, *Tie2*^Cre^-mediated *Lpp3* deletion likely also altered smooth muscle cell survival. Next, we isolated ECs from *Tie2^Cre^* (*WT*) or *Lpp3^fl/fl^* embryos cultured for 4 days. Adenovirus particles encoding Cre/eRFP (red fluorescent protein) were added to these cells and cell extracts prepared after 18 h of infection. The basal expression of the proapoptotic mediator p53 and its target p21 protein was low in *WT*-ECs, whereas in *MT-*ECs, their expression levels increased (*Figure [4](#CVW090F4){ref-type="fig"}J*). We also analysed *WT* and *MT* protein lysates for the presence of Flk1 and Cre; the findings provided information regarding EC characteristics and Cre expression levels (*Figure [4](#CVW090F4){ref-type="fig"}J*). To examine EC integrity, we performed TEM analysis (*Figure [4](#CVW090F4){ref-type="fig"}K*). TEM analyses of *WT*-sections revealed normal ECs with intact vascular walls (*Figure [4](#CVW090F4){ref-type="fig"}K*), whereas MT-sections displayed occurrence of membrane blebbing, condensed nuclei, and (*Figure [4](#CVW090F4){ref-type="fig"}K*, white arrowheads) and near-apoptotic ECs (*Figure [4](#CVW090F4){ref-type="fig"}*, blue asterisk). In addition, staining of lung tissue sections prepared from E13.5 *WT*- ([Supplementary material online, *Figure S3A*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvw090/-/DC1), top panels) and *MT*-sections ([Supplementary material online, *Figure S3B*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvw090/-/DC1), bottom panels) with anti-cleaved caspase-3 showed the presence of apoptotic vascular cells in *MT*-embryos ([Supplementary material online, *Figure S3B* and *C*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvw090/-/DC1)). Furthermore, purified *MT*-ECs showed strongly positive staining for anti-cleaved caspase-3 (data not shown). Figure 4Presence of apoptotic ECs in developing E13.5 *Lpp3^ECKO^* (*MT*) embryos. (*A*) Very few apoptotic ECs are seen in *WT* (*tg.Tie2^Cre^*) E13.5 embryo. (*B*) *MT* sections show numerous apoptotic ECs in the haemorrhagic region of the head. (*C*) Normal developing blood vessels in head region of *WT* embryo. (*D*) *MT* embryo shows presence of apoptotic ECs (arrows). (*E*) *WT* embryo section showing normal microvessels. (*F*) Apoptotic ECs lining the microvessels (black arrows). (*G* and *H*) Magnified images of E and F, respectively. Dark brown stainings indicate apoptotic ECs. (*I*) Quantification of apoptotic ECs. The data represent the mean ± SEM. *n* = 5 from three independent experiments. (*J*) Relative abundance of proteins in WT-ECs and MT-ECs total lysates were analysed by WB with indicated antibodies. Equal loading of proteins across the lanes were determined with anti-Cre antibody. (*K*) Densitometric quantifications of WB signal intensity, fold change from the background (background was considered as one-fold) are shown, *n* = 4--5. \**P* \< 0.05, by the Student unpaired *t*-test. The data are the means ± SEM. (*L*) Top panels: TEM analyses of the microvessels in (E13.5) *WT*- and *MT*-embryos. ECs lining the endothelium of *MT* embryos show membrane blabbing (white arrows), and presence of intercellular gaps in between adjacent ECs. Bottom panels: magnified view of the blood vessels showing altered EC--EC adhesion structures and frequently shows condensed and fragmented nuclei (\*). Magnifications are as shown. E, erythrocyte. Images are representative of three independent experiments in which 9--12 separate embryos were evaluated (*n* = 9--12).

3.4. Decreased VE-cadherin and fibronectin expression in *Lpp3^ECKO^* ECs {#s3d}
-------------------------------------------------------------------------

To determine the role of LPP3 in cardiovascular patterning defects, we prepared sections of large blood vessels from E13.5 mouse embryos and immunostained them with anti-VE-cadherin and anti-fibronectin antibodies. As opposed to *WT-*sections, *MT-*sections showed decreased expression of VE-cadherin and reduced deposition of fibronectin; however, no appreciable alteration was observed with anti-CD31 (*Figure [5](#CVW090F5){ref-type="fig"}A--D*). Figure 5Decreased VE-cadherin and fibronectin in E13.5 *Lpp3^ECKO^*. Sections prepared from the head region of E13.5 were stained with (*A*) anti-fibronectin (green) decorated mostly the basement membrane of the vascular wall. (*B*) Decreased fibronectin immunoreactivity in the *MT* section. (*C*) VE-cadherin and CD31 were detectable in the *WT* section. (*D*) Decreased VE-cadherin immunoreactivity in the *MT* section. The lower panels represent magnified images (×40) of top panel pictures. ECs were isolated from E13.5-day-old embryos using anti-Flk1 and anti-CD31^+^ beads (please see methods) and as previously described.^[@CVW090C30]--[@CVW090C32]^. (*E*) Purity of isolated mouse ECs: representative FACS profiles of mouse ECs with control IgG, anti-CD31, and anti-Flk1 antibodies. (*F*) qRT-PCR data obtained from *WT*- and *MT*-ECs are as shown. Primer pairs for used for amplifying *Hprt*, *Lpp3*, *Lpp2*, *CycD1* (*Cyclin-D1*), *VEcad* (*VE-cadherin*), *Flk1*, *Fbrctn* (*fibronectin*), *Klf2*, and *Klf4* genes are listed in *Table [1](#CVW090TB1){ref-type="table"}*. Values are expressed as the mean ± SEM. Experiments were performed three times independently with three technical triplicates and expression normalized to *Hprt*. \**P* \< 0.05, *n* = 9--10 embryos, '*n*' represents the number of individual embryos used. (*G*) Representative images of CD31^+^ and Flk1^+^ *WT*- and *MT*-ECs cultured for 4 days on gelatine-coated glass coverslips were stained with anti-VE-cadherin antibody (green) and DAPI (nucleus, blue); compared with *WT*-ECs, *MT*-ECs expressed reduced VE-cadherin. Magnifications are as shown.

Next, we isolated ECs from E12.5 *WT-* and *MT*-embryos as described in the methods; the procedure was as reported in previous studies.^[@CVW090C30]--[@CVW090C32]^ Endothelial identity was confirmed using flow cytometry analysis with control IgG, anti-CD31, and anti-Flk1 antibodies (*Figure [5](#CVW090F5){ref-type="fig"}E*). Next, using these isolated ECs, we performed a qRT-PCR assay to identify the target genes involved in Lpp3-regulated angiogenesis. After overnight growth factor starvation, total mRNAs were prepared from *WT-* and *MT*-ECs, and the expression levels of candidate genes and EC genes in these cells were determined. Notably, in this assay (*Figure [5](#CVW090F5){ref-type="fig"}F*), the basal expression of *Lpp3*, *Lpp2*, *Cyclin-D1*, *Flk1*, *VE-cadherin*, and *fibronectin* was readily detectable in *WT*-ECs, whereas *MT-*ECs exhibited reduced expression of *Lpp3*, *Cyclin-D1*, *VE-cadherin*, and *fibronectin* in the ECs that were cultured under serum-free and growth factor-free culture conditions (*Figure [5](#CVW090F5){ref-type="fig"}F*). This result suggests that *Cyclin-D1*, *VE-cadherin*, and *fibronectin* are regulated directly or indirectly by Lpp3. The morphology of *WT*- and *MT*-ECs is shown in *Figure [5](#CVW090F5){ref-type="fig"}G*.

3.5. Loss of EC-*Lpp3* results in increased susceptibility to endothelial barrier disruption {#s3e}
--------------------------------------------------------------------------------------------

The interaction of cytoplasmic domain of VE-cadherin with β-catenin and p120ctn proteins are critical for neovessel stability and endothelial barrier function.^[@CVW090C3],[@CVW090C4],[@CVW090C6]^ While examining H&E sections of *MT* embryos, we also observed defective lung development (data not shown), which was likely due to defective EC integrity. To test the hypothesis that the loss of LPP3 results in increased vascular permeability of LMVECs, we plated LMVECs on gold-plated electrodes and allowed them to form a confluent monolayer; subsequently, a knockdown experiment was performed using the *control shRNA* and the *LPP3-shRNA* retroviral particles. The timeline of the experiment is shown in *Figure [6](#CVW090F6){ref-type="fig"}A*. As shown in *Figure [6](#CVW090F6){ref-type="fig"}B*, in one group of LPP3-depleted LMVECs, *β-catenin cDNA* was transfected transiently, whereas in the second group, *p120ctn cDNA* was transfected. In LPP3-depleted LMVECs, the baseline TER value and the permeability decreased, whereas in the control group, no appreciable changes were observed. The addition of thrombin (50 nM) to the LMVEC monolayer decreased the resistance, which gradually returned to baseline, indicating re-annealing of the LMVEC monolayer. Thrombin significantly decreased the TER of LMVEC monolayers after *LPP3* knockdown (*Figure [6](#CVW090F6){ref-type="fig"}B*); this defect was partially restored following transfection with a retrovirus encoding *β-catenin cDNA*, whereas *p120ctn* had no effect. The efficiencies of knockdown and cDNA transfections were analysed by WB (*Figure [6](#CVW090F6){ref-type="fig"}C)*. The data suggest that the loss of *Lpp3* is incompatible with vascular EC barrier integrity, which can be rescued, in part, by β-catenin but not by p120ctn. Figure 6*LPP3-*knockdown results in increased vascular endothelial cell permeability. (*A*) Timeline of the knockdown, β-catenin cDNA transfection, and TER assay. (*B*) LPP3-depletion results in decreased TER and increased LMVECs barrier disruption, whereas no change was observed in LMVECs receiving control *shRNA*. Following transfection of *β-catenin cDNA* into LPP3-depleted LMVECs, the TER level was restored nearly to control group, while the transfection with *p120-catenin cDNA* into LPP3-depleted LMVECs had only a modest effect. Experiments were carried out in triplicates and repeated at least three times; \**P* \< 0.05. (*C*) The efficiency of *Lpp3*-knockdown was assessed by WB with the indicated antibodies. Experiments were repeated at least three times with similar results.

3.6. β-catenin, but not p120ctn, restores the effect of Lpp3 loss {#s3f}
-----------------------------------------------------------------

Proliferation of ECs and the formation of branching point structures represent hallmarks of angiogenesis. To determine if LPP3 plays a role in these processes, ECs isolated from E13.5 *MT* and *WT* embryos were subjected to cell proliferation assays; the timeline of this experiment is shown in *Figure [7](#CVW090F7){ref-type="fig"}A*. As opposed to 42 ± 4.5% incorporation of BrdU observed in *WT*-ECs, *MT*-ECs showed only 11 ± 3.25% BrdU incorporation (*Figure [7](#CVW090F7){ref-type="fig"}B* and *D)*. However, the decreased proliferation was rescued, in part, by transfection of *MT*-ECs with a retrovirus particle encoding *β-catenin cDNA* (*Figure [7](#CVW090F7){ref-type="fig"}B* and *E*). Representative images of BrdU incorporation assays are shown in *Figure [7](#CVW090F7){ref-type="fig"}C--E*. WB analyses showed decrease in β-catenin, VE-cadherin, cyclin-D1, and fibronectin expression in the *MT-*ECs; however, the effect of Lpp3 loss was partially restored by *β-catenin cDNA* transfection (*Figure [7](#CVW090F7){ref-type="fig"}F*). The use of the anti-fibronectin antibody revealed immature (fast-moving) forms of fibronectin polypeptide species, raising the possibility that LPP3 regulates the maturation of fibronectin at the translational level as well. However, we did not investigate this phenomenon in detail. The expression of the Cre enzyme was determined using anti-Cre antibodies and equal loading with anti-GAPDH antibodies (*Figure [7](#CVW090F7){ref-type="fig"}F*, lowermost panels). The relative fold change in WB signal intensities is shown in *Figure [7](#CVW090F7){ref-type="fig"}G*. Next, we plated *WT*-ECs, *MT*-ECs, and *MT*-ECs receiving *β-catenin cDNA* onto Matrigel to examine the ability of these cells to form branching point structures. The strategy and the timeline of formation of the branching point structures are shown in *Figure [7](#CVW090F7){ref-type="fig"}H*. As shown in *Figure [7](#CVW090F7){ref-type="fig"}I* and *J*, as expected *WT*-ECs formed branching point structures, whereas *MT*-ECs (*Lpp3^ECKO^*) showed a significantly reduced number of branching point structures over the same period (*Figure [7](#CVW090F7){ref-type="fig"}I* and *K)*. Transfection with retrovirus particles encoding *β-catenin cDNA*- into *MT*-ECs restored the ability of *MT*-ECs to form branching point structures, but not to the same extent as that for *WT-*ECs (*Figure [7](#CVW090F7){ref-type="fig"}I* and *L*). Figure 7Loss of Lpp3 results in decreased angiogenic activities of ECs. (*A*) The timeline of the BrdU incorporation experiment. Flk1^+^ and CD31^+^ ECs isolated from (E13.5) *WT*- and *MT*-embryos as described in Methods were subjected to BrdU assay. (*B*) Quantification of BrdU^+^ ECs was performed on *WT*, *MT*, and *MT*-ECs transfected with β-catenin cDNA. White arrowheads indicate BrdU^+^ ECs. ECs were lightly counterstained with eosin. Data represent mean ± SEM. *n* = 3--5, \**P* \< 0.05 vs. control. Experiments were repeated three times with triplicates. (*C--E*) Representative images of the BrdU assay. (*F*) WB analyses of total lysates prepared from *WT*, *MT*, *MT*-ECs receiving β-catenin cDNA ECs were subjected to immunoblotting analyses with indicated antibodies. Molecular weights, in kilo Daltons (kDa). (*G*) Densitometric quantifications of WB signal fold intensity change from Cre (Cre expression level was considered as one-fold) are shown, *n* = 5--6. \**P* \< 0.05, by the Student unpaired *t*-test. The data are the means ± SEM. (*H*) Strategy and timeline of formation of endothelial branching point structure assay. (*I*) Quantification of branching point structures. Data are expressed as a percentage of branching points (*n* = 3, \**P* \< 0.05 vs. control). The experiments were repeated three times with the use of triplicate wells. (*J*--*L*) Representative phase contrast images of branching point structures of CD31^+^ and Flk1^+^ *WT*-, *MT*- and *MT*-ECs receiving *β-catenin* cDNA (2 × 10^5^) were plated onto growth factor reduced Matrigel in the presence of bFGF (10 ng/mL) and VEGF^165^ (50 ng/mL). After 18 h, the numbers of branching points were enumerated in 10 randomly selected ×20 microscopic fields. Magnifications are as shown. The black arrows indicate branching points. Experiments were repeated at least three times with similar results.

4.. Discussion {#s4}
==============

Here, we showed that Lpp3 is essential for some aspects of cardiovascular development in the mouse embryo between E8.5 and E13.5. Embryos lacking EC-Lpp3 developed cardiovascular defects that were different from those described in *Lpp3*-deletion experiments,^[@CVW090C24]--[@CVW090C27]^ demonstrating that signalling pathways mediated through Lpp3 are crucial for normal embryonic development. Specifically, (i) EC-*Lpp3* deficiency led to embryonic deaths in two waves; (ii) *Lpp3^ECKO^* embryos developed haemorrhages and apoptotic ECs secondary to the loss of barrier integrity; (iii) in *Lpp3^ECKO^* ECs, the expression of *cyclin-D1*, *VE-cadherin*, *fibronectin*, *Klf2*, and *Klf4* decreased; and (iv) the re-expression of *β-catenin* in *Lpp3*^ECKO^ ECs partially restored the effect of the loss of LPP3, whereas *p120ctn* did not. Together, these results indicate a crucially important role for LPP3 in the maintenance of EC barrier function and angiogenesis.

The expression of Lpp3 is seen in ECs at E8.5 in several different vascular bed.^[@CVW090C24]^ In cultured cells, LPP3 is predominantly localized at the cell--cell junctions to maintain the steady-state levels of S1P.^[@CVW090C18],[@CVW090C19]^ We used *Tie2^Cre^* because it is a well-established system, the endothelial expression of *Tie2* is known, and its strong expression in ECs occurs as early as E8.5,^[@CVW090C40]--[@CVW090C42]^ but also expressed by a subset of monocytes and macrophages, and may also be by mesenchymal cells.^[@CVW090C28]^ However, what might be the reason(s) for the embryonic deaths in two waves? One could surmise that the variable level of expression of *Tie2^Cre^* likely contributed to the embryonic lethality in two waves, that is to say, the first wave of lethality (with severe phenotype) could have been due to uniform and robust nature of *Tie2^Cre^* expression throughout all vascular bed. Conversely, the expression of *Tie2^Cre^* could have been delayed in embryos that displayed mild phenotype. Alternatively, the simplest explanation could be a spectrum of penetrance causing severe and mild phenotypes. In this regard, Escalante-Alcalde *et al.* described *Lpp3*^−/−^ embryonic deaths associated with two distinct phenotypes, one '*Fused*/Axin deficiency-like' and the other 'frizzled5 deficiency-like' phenotypes, but their study did not elaborate the exact biochemical mechanisms responsible for these two phenotypes.^[@CVW090C24]^ However, we addressed the ability of LPP3 to titrate β-catenin signalling activities in (i) sub-confluent ECs, LPP3 activated β-catenin signalling, but (ii) confluent ECs, LPP3 down-regulated β-catenin signalling.^[@CVW090C22]^ Here, we show that LPP3 is a positive regulator of cardiovascular development and that it is an essential enzyme; we also provide a new mechanism of regulation of apoptosis by LPP3 and EC barrier integrity via β-catenin signalling activities. Most importantly, a subset of embryos showed a decrease in EC proliferation, accompanied by increased apoptosis, and defects in heart development that were likely secondary to defective EC behaviour. A defect in branching is also likely due to reduced EC migration and inability to form cell--cell adhesion structures. We also observed thickened blood vessels, but these effects were not statistically significant. At times, the *Lpp3^ECKO^* embryos exhibited large avascular regions between blood vessels. The lack of productive angiogenesis suggested that the reciprocal relationship between the levels of cell proliferation and apoptosis, which entails the survival mechanism, is controlled by LPP3. To our knowledge, this study is the first to demonstrate the critical role of LPP3 in the regulation of blood vessel development between E11.5 and E13.5.

Neovessel growth and remodelling during embryonic development are regulated by precise signals that determine the orderly nature of angiogenesis. *Tie2^Cre^*-mediated deletion of *Lpp3* in ECs and haematopoietic cells in mice resulted in embryonic lethality. A significant number of *Lpp3*^ECKO^ embryos died within E11.5--E13.5, and genotyping of ECs collected from these embryos indicated that the expression of Lpp3 was lost, with no appreciable changes in Lpp2 or Lpp1 levels. LPP2 protein levels also did not change in Lpp3-deficient ECs, suggesting that LPP2 cannot compensate for the loss of LPP3. We observed an appreciable number of abnormal embryos at E8.5--10.5 (first wave of lethality); however, detailed analysis of these embryos was difficult due to their small size and fragility. Visual examination of these embryos revealed the presence of blood vessel disruption and localized haemorrhages. CD31 staining revealed the presence of ECs in the *WT*- and *MT*-embryos. CD31 staining also confirmed the presence of haemorrhage and defective neovessels in the *Lpp3*^ECKO^ embryos. H&E staining confirmed the presence of defective blood vessels. However, we could not establish the precise haemorrhage or vascular leakage sites. Therefore, we carried out immunofluorescence staining using EC markers. Staining paraffin-embedded sections and fixed cultured cells with antibodies has some limitations in that the specificity and the avidity of each antibody are different and the epitope(s) are often not fully exposed. Thus, to limit over-interpretation of our data, we used only those antibodies that have been used in many studies. With the use of CD31 staining, it was clear that ECs were present in the *Lpp3*^ECKO^ embryos; however, the angiogenic activities of these cells were limited. We observed decreased fibronectin and VE-cadherin levels in the *Lpp3*^ECKO^ embryo sections. Staining with anti-smooth muscle α-actin antibodies was inconclusive (data not shown).

During angiogenesis, dynamic sprouting ensures that ECs are in contact with each other, e.g. via VE-cadherin-mediated AJs, and it requires the presence of appropriate ECM proteins such as fibronectin. Sprouting ECs secrete high levels of fibronectin^[@CVW090C1],[@CVW090C2]^; however, fibronectin is also secreted by several other cell types. Fibronectin is a multifunctional ECM protein, as it not only presents the RGD sequence to integrins but also signals through the FAK and Shc pathways.^[@CVW090C43]^ As fibronectin and VE-cadherin proteins regulate multiple aspects of angiogenesis and EC barrier integrity, decreased secretion of fibronectin by Lpp3-defecient ECs could impede adhesion events and integrin signalling, which might induce EC apoptosis.^[@CVW090C1]--[@CVW090C5],[@CVW090C43]^ Thus, the observed phenotype of increased permeability and haemorrhage in MT embryos is consistent with known functions of fibronectin and VE-cadherin. The loss of EC-Lpp3 decreased the expression of β-catenin and VE-cadherin, two of the most important adhesion proteins that are critical for EC integrity and survival. Although Lpp2 and Lpp3 share the same substrates, the Lpp2 level remained unchanged, suggesting that the loss of Lpp3 in ECs cannot be compensated by Lpp2. Most studies have described LPP3 enzymatic activity, and because it has numerous substrates, the rescue experiments are problematic. However, β-catenin could rescue the effect of Lpp3 loss. These results indicate that β-catenin not only mediated Wnt signalling but also mediated cell--cell adhesion by binding to the cytoplasmic domain of VE-cadherin.

How does LPP3 stabilize β-catenin? This question has been previously addressed by us^[@CVW090C22]^; therefore, we focused on delineating the downstream events after β-catenin stabilization. Thus, the *Lpp3* deletion primarily altered ECs behaviour due to decreased levels of β-catenin and VE-cadherin proteins and decreased expression of *Cyclin-D1*, *VE-cadherin*, *fibronectin*, *Klf2*, and *Klf4* genes. Because β-catenin is involved in cell adhesion and has the ability to act as a transcriptional regulator, it has been difficult to uncouple the control of transcriptional activities from that of cell adhesion events. Therefore, we were not surprised to find decreased expression of *Cyclin-D1*, *VE-cadherin*, *Fibronectin*, *Klf4*, and *Klf2* genes that are known downstream targets of β-catenin transcriptional activities*.* Thus, we postulate that Lpp3 deficiency in the vasculature decreases the expression of these genes below the optimal level that is required for normal EC development, as LPP3 likely regulates endothelial responses to athero-relevant haemodynamic forces.^[@CVW090C44],[@CVW090C45]^ Our study provides evidence that Lpp3, at least in ECs and in a subset of haematopoietic cells, plays a pro-survival role in the formation of neovessels during embryonic development. MT-embryos frequently showed striking cardiac defects. MT hearts were poorly developed as only intact structure in these hearts was the thin epicardium; importantly, in the MT-embryos, the myocardium and the endocardium were less developed, with thin ventricular wall and the cardiac cushions clearly absent. The observed insufficient myocardial trabeculation and decreased compact wall were likely to be caused by reduced β-catenin signalling and fibronectin secreted by the *Lpp3^ECKO^* ECs, and due to the disruption of blood vessel formation. Fibronectin deposition and assembly are required for cardiomyocyte migration and proliferation.^[@CVW090C1],[@CVW090C2],[@CVW090C46],[@CVW090C47]^ Fibronectin-mediated α4-integrin signalling has also been shown to control cardiac development.^[@CVW090C48]^ Because endothelial cardiomyocyte interaction is also required for normal cardiac development and growth, EC death may affect cardiomyocyte survival and growth. Recently, S1P has been suggested to act as a negative regulator of angiogenesis at some point during embryonic development.^[@CVW090C49],[@CVW090C50]^ We observed that the *Lpp3^ECKO^* resemble *Cattnb^fl/fl^::tie2^Cre^* embryos in their timing of lethality and head haemorrhage phenotype.^[@CVW090C5]^ Thus, it would be interesting to examine if genetic overexpression of EC *β-catenin in vivo* (i.e., *Cattnb*^lox(ex3)/lox(ex3)^) could rescue any of the haemorrhage or other vascular defects seen in *Lpp3^ECKO^*. Future studies should address this intriguing question. Taken together, our study illuminates a crucially important function of LPP3 in ECs as a positive modifier of cardiovascular development.

Three independent genome-wide association study revealed a link between a frequently occurring variation in the *LPP3* (*PPAP2b*) loci and an increased risk of coronary artery disease.^[@CVW090C51]--[@CVW090C53]^ Recent review articles have described the putative role of LPP3 to increased risk of cardiovascular disease.^[@CVW090C44],[@CVW090C54]^ Thus, the results presented in this study indicate that the loss of Lpp3 in ECs and in a subset of *Tie2*-expressing haematopoietic cells impairs the development of functional vasculature. Importantly, we demonstrate that Lpp3 is a modifier of normal embryonic blood vessel development. Our study also reveals an unusual mechanism of a lysolipid phosphatase in the regulation of vascular development; therefore, we propose that LPP3 acts as a 'gatekeeper' of normal EC homeostasis.
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